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1 Microorganisms are one of the most important
sources of new bioactive compounds such as antibi
otics, immunosuppressants, antiparasitics, antitu
mor and hypocholesterolemic agents and enzyme
inhibitors [1–4]. Many compounds which were first
discovered as antibiotics failed in their later stages of
development as antibiotics, but proved to be good
antitumor, antimigraine, immunosuppressive and
antiparasitic agents [1]. Each year millions of people
are diagnosed worldwide with cancer, and more than
half of these patients eventually die from this disease.
Based on global cancer statistics published in the year
2011, 12.7 million cases of cancer were detected and
7.6 million cancer deaths in a year are reported [5].
Hepatocellular carcinoma is one of the most com
mon malignancies throughout the world [6]. It is
characterized by high incidence in hepatitis B virus
associated liver diseases [7]. The present work is tar
geted against hepatocellular cancer cells. Conven
tional cancer treatments such as surgery, chemother
apy and radiotherapy often fail to achieve a complete
cancer remission. Moreover, it has been widely rec
ognized that radiotherapy or chemotherapy are likely
to cause significant side effects. This fact has
prompted the development of many new approaches
for the treatment of cancer. One such example is the
use of live, attenuated bacteria or their purified prod
uct. Microbial based therapy of cancer is one of the
emerging cancer treatment modalities [8]. The use of
bacteria in the regression of certain forms of cancer
1 The article is published in the original.
has been recognized for more than a century [9].
Important advances have been made to study and
develop live bacteria or bacterial products such as
proteins, enzymes, immunotoxins and secondary
matabolites which specifically target cancer cells and
cause tumor regression through growth inhibition,
cell cycle arrests or apoptosis induction [10–13]. The
other reason for using the microbial metabolites for
anticancer activity was due to their high antioxidant
activity by 2,2'azinobis(3ethylbenzothiazoline
6sulphonic acid) method which proves that they
have free radical scavenging activity [14]. The aim of
the study was to screen metabolites from Bacillus
cereus and Bacillus pumilus for anticancer potential
and to test their anticancer activity by nuclear stain
ing studies and DNA fragmentation analysis.
MATERIALS AND METHODS
Reagents. All cultivation media components were
purchased from Himedia (India). Chang liver cells
(normal human liver cell lines), HepG2 (human can
cerous liver cell lines) and Hep2 (human laryngeal
epithelial carcinoma cell lines) were procured from
the National Centre for Cell Sciences (NCCS) in
Pune (India). Chemicals and solvents were pur
chased form Merck (Germany). Minimum essential
medium (MEM), (34,5Dimethylthiazol2yl)
2,5diphenyltetrazolium bromide, a tetrazole)
(MTT), fetal calf serum, antibiotics and acridine
orange were obtained from Sigma Chemicals Co.
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(USA). Dimethyl sulfoxide (DMSO) was purchased
from SD Fine Chemicals Ltd. (India).
Isolation and maintenance of bacterial cultures.
Soil samples were collected from a hill station nearby
Shimoga region, Karnataka (India). The microorgan
isms presented in the soil were screened for their anti
biotic production potential by crowded plate tech
nique [15]. Two bacteria with broad range of antibac
terial activity were selected for further screening of
their metabolites for anticancer activities. The two
bacteria selected were identified as Bacillus cereus and
Bacillus pumilus by lipid profile method [16] in
National Institute of Oceanography, Kochi. The iso
lated pure cultures of B. cereus and B. pumilus were
grown separately on nutrient agar medium [15] for
24 h at 35°C, and stored at 4°C until use.
Solvent extraction and preparation of samples.
Both the bacteria were grown in nutrient broth
medium by incubation at 35 ± 2°C for 3 days to
obtain the metabolites. The broth was centrifuged at
2000 g for 20 min to remove the cells. The cellfree
culture supernatants containing the metabolites were
collected. After confirming antibacterial activity, the
culture supernatants of both microorganisms were
subjected to successive solvent extraction with petro
leum ether, ethyl acetate or methanol (1 : 1) in a sep
arating funnel. The obtained extracts were dried in
separate plates to get thick, viscous compounds.
These substances obtained from B. cereus were fur
ther separated and numbered as sample fractions
from BC1 to BC5 as shown in the Fig. 1.
Similarly, sample fractions from BP1 to BP5 were
obtained from B. pumilus. The sample fractions from
BC1 to BC5 and from BP1 to BP5 were subjected to
in vitro cytotoxicity studies by 3−(4,5−dimethylthiazol
2yl)2,5diphenyltetrazolium bromide (MTT) assay.
In vitro cytotoxicity studies. HepG2, Hep2 and
Chang liver cell lines were used for the study. The sam
ple fractions obtained as described in the above section
were subjected to in vitro cytotoxicity studies by
MTT assay [17].
The cell lines were cultured in MEM. The medium
was supplied with 10% fetal calf serum, penicillin
(100 IU/mL) and streptomycin (100 µg/mL).
Cytotoxicity screening was carried out by determi
nation of activity of mitochondrial succinate dehydro
genase by microculture tetrazolium assay [17].
The monolayer cell culture was trypsinized using
combination of 0.2% trypsin and 0.5% EDTA. Cells
were exposed to trypsin at 37°C for 3 min. The cell
number was adjusted to 1.0 × 105 cells/mL using MEM
containing 10% fetal calf serum [18]. To each well of
the 96 well microtitre plate, 0.1 mL of the diluted cell
suspension containing approximately 10.000 cells was
added. After 24 h, when a partial monolayer of cells
was formed, the supernatant was flicked off, washed
with 1 mM phosphate buffer (pH 7.3) and 100 µL of
different B. cereus (BC1 to BC5) and B. pumilus
(BP1 to BP5) sample fractions were added. The
plates were incubated at 37°C for 3 days in 5% CO2
atmosphere, then microscopic examination was made
and observations were recorded for each 24 h. After
72 h, the drug solutions in the wells were discarded and
50 µL of MTT in MEM was added to each well. The
plates were gently shaken and incubated for 3 h under
the same conditions. The supernatant was removed,
50 µL of propanol was added and the plates were gen
tly shaken to solubilize the formed formazan. The
absorbance was measured using a microplate reader
(BioRad, USA) at 540 nm. The percentage growth
inhibition values were calculated using the formula as
given below.
% growth inhibition
=  100
mean OD540 of individual test group( )
mean OD540 of control group
 100.×–
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Fig. 1. Schematic diagram of preparation of B. cereus sample fractions.
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Nuclear staining studies. Single cover slip was
placed in each well of 6 wells microtitre plate. The
monolayer HepG2 cell culture was trypsinized, the
number of cells was adjusted to 50000 cells/mL and
2.5 mL of cell suspension was added drop by drop on
cover slip in each well. After partial monolayer was
formed, sample fractions of BC1 and BC3 prepared
at different concentrations in maintenance medium
cell culture were added. The control well contained
only maintenance medium. The plates were incubated
at 37°C in 5% CO2 atmosphere. After overnight incu
bation, medium from wells was discarded and cells
were washed with 10 mM phosphate buffer (pH 7.3,
PBS). The cells were fixed with 1 mL of 90% methanol
at 20°C for 20 min. The methanol was removed,
replaced with acetone and kept for 10 s. After fixing,
cells were washed with ice cold PBS for 2–3 times.
The cells were incubated with PBS containing
1% BSA and 0.1% triton X100 at 37°C for 30 min.
Plate was washed with PBS for 2–3 times, 100 µL of
0.01% acridine orange in PBS (pH 7.4) was added and
incubated at 37°C for 20 min. The cover slip was
washed thrice with PBS and placed on the slide. The
cover slips were observed under fluorescent micro
scope for any nuclear changes [10].
DNA fragmentation analysis. DNA was extracted
from HepG2 cells. The liver cells were treated with
25 mM Tris–HCl buffer (pH 7.5) containing
0.5% SDS, 0.5 mg/mL proteinase K and 5 mM EDTA
at 55°C for 1 h. After treatment of the cells with
phenol : choloroform : isoamyl alcohol (25 : 24 : 1,
vol/vol) and chloroform : isoamyl alcohol (24 : 1,
vol/vol) mixtures, DNA was precipitated with
3M sodium acetate (pH 5.2) and absolute ethanol.
After washing with 10 mM phosphate buffer (pH 7.4)
DNA was dried and resuspended overnight at 37°C
with 1 mM Tris⎯EDTA buffer (pH 7.0) containing
100 µg/mL RNase A [17].
The extracted DNA was treated with the sample
fractions BC1 and BC3 (200 µg/mL) at 37°C for
12 h. The control untreated DNA and DNA treated
with the BC1 and BC3 were subjected to agarose gel
electrophoresis. The DNA fragmentation patterns
were observed.
Agarose gel electrophoresis. Agarose gel electro
phoresis was performed according to available stan
dard protocol of GENEi teaching kit (India). After
electrophoresis, the bands were observed in UV light,
gel pictures were captured, saved and analyzed using
Alphaimager software (USA).
RESULTS AND DISCUSSION
In an attempt to find novel bacteria with antibiotic
production potential and other pharmacological activi
ties, 2 bacteria were isolated from soil samples collected
in Shimoga region, Karnataka (India) and identified as
B. cereus and B. pumilus with potent antibacterial and
antioxidant activities. B. cereus has been reported to
produce enterotoxins [16], antibacterial [17] and anti
fungal compounds [18]. The literature survey suggests
that some Bacillus species have shown anticancer
activities. For example, a marine Bacillus SW31 has
shown growth inhibition and apoptosis of head and
neck cancer cells [19]. The cytotoxicity results of this
study revealed that B. cereus metabolites have com
pounds with anticancer properties.
Among the studied samples, the fraction BC1
showed CTC50 (cytotoxicity 50%) value of
225.4 µg/mL against HepG2, 152.2 µg/mL against
Hep2 and 659.3 µg/mL against Chang liver cells
(table). This result demonstrated that fraction BC1
was more specific towards cancer cells in comparison
with normal cells than fraction BC3. All other frac
tions obtained from B. cereus (BC2, BC4 and BC5)
and B. pumilus (from BP1 to BP5) revealed cytotox
icity towards both normal as well as cancer cells, and
were not specific against cancer cells. Taking into
account this result, BC1 and BC3 fractions were
taken up for further anticancer studies using nuclear
staining method. The action of the metabolites from
B. cereus demonstrating cytotoxic and apoptotic effect
was comparable with that from Bacillus vallismortis
reported by Jeong et al. [23]. The cancer HepG2 and
Hep2 cell lines used in the present work differed from
the similar earlier studies. Cytotoxicity studies have
confirmed that sample fractions BC1 and BC3 were
Cytotoxicity action (CTC50) of various B. cereus (BC1 to
BC5) and B. pumilus (BP1 to BP5) sample fractions on
different normal and cancer cell lines
Sample
 fraction
CTC50, µg/mL
HepG2               Chang liver Hep2
BC1 225.4 659.3 152.2
BC2 218.5 207.5 1050.2
BC3 228.3 351.8 282.2
BC4 147.0 104.8 97.9
BC5 323.3 223.5 715.3
BP1 237.4 52.7 282.2
BP2 209.1 170.0 109.7
BP3 200.1 258.0 159.9
BP4 179.0 103.1 54.6
BP5 350.3 253.6 310.2
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toxic towards cancer cells. Some of the important
antitumor compounds used for chemotherapy antibi
otics are produced by microorganisms [24–25]. Many
bacteria such as Clostridium, Bifidobacterium, Salmo
nella, Mycobacterium, Bacillus and Listeria have been
reported the ability to selective action against target
cancer cells by grooving in the hypoxic core regions of
solid tumors [26]. Not only live bacteria but also prod
ucts derived from microorganisms have been tested
and some of them are successfully used as anticancer
agents. The mode of action is connected with the pro
duction of cytotoxic factors, enzymes, antibiotics and
other secondary metabolites. SSL proteins produced by
Staphylococcus aureus and capable to bind “Gprotein”
receptors which are overexpressed in cancer cells;
enzyme called “Ma–ADI” inhibiting tumor growth
obtained from Mycoplasma arginini and “epothilones”,
a cytotoxic metabolites with anticancer activity secreted
by Sporangium cellulosum are a few examples [27–28].
From the results obtained by nuclear morphology
studies, it was evident that sample fractions BC1 and
BC3 showed nuclear morphological changes similar
to apoptotic cell morphology in cancerous cell culture
HepG2 (Fig. 2). In normal cell culture tested, there
was no such nuclear morphological change. This in
vitro experiment has proved the selective toxicity of
fractions BC1 and BC3 against cancer cells. Nuclear
staining studies have showed that sample fractions
induced apoptosis cell death in liver cancer cells.
The promising result of nuclear staining was the
basis for further screening of the same fractions by
DNA fragmentation analysis. It was shown that the
control DNA had intact band but DNA treated with
BC1 and BC3 fractions revealed damaged fragmen
tation patterns (Fig. 3). DNA fragmentation studies
have further confirmed that sample fractions caused
damage of the cancer cell DNA.
Bacillus thuringiensis, one of the closely related
species to B. cereus, has been reported to produce
unique proteinaceous crystalline parasporins during
sporulation with potential cytotoxic and anticancer
activity against a number of cancer cell lines [29]. The
production of crystalline parasporins is the only fact
that discriminates between the two taxonomically
closely related species, B. thuringiensis and B. cereus
[30]. This study suggests that the compounds respon
(a) (b)
(c)
Fig. 2. Nuclear staining of HepG2 cells using acridine orange under fluorescent microscope. a—control cells; b—apoptotic cell
morphology of cells treated with fraction BC1 (200 µg/mL); c—apoptotic cell morphology of cells treated with fraction BC3
(200 µg/ mL). Arrows indicate the membrane blebbing.
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sible for anticancer property of the present isolate
B. cereus are different from parasporins produced by
B. thuringiensis. The mass spectroscopy of TLC frac
tions of BC1 and BC3 has revealed that they do not
contain proteins (data not shown). Further purifica
tion of the TLC fractions and their spectral analysis
may provide a lead molecule which can be taken up for
in vivo activity and preclinical anticancer studies.
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1 2 3
Fig. 3. DNA fragmentation studies of fractions BC1 and
BC3 in agarose gel electrophoresis. Lane 1—untreated
HepG2 cells; lane 2—HepG2 cells + cells treated with
fraction BC1 (200 µg/mL; overnight); lane 3—HepG2
cells + cells treated with fraction BC3 (200 µg/mL; over
night).
